A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma

@inproceedings{JesusAcosta2011AMA,
  title={A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma},
  author={Ana de Jesus-Acosta and George R. Oliver and Amanda Blackford and Katharine Kinsman and Edna I. Flores and Lalan S. Wilfong and Lei Zheng and Ross C. Donehower and David Peter Cosgrove and Daniel A. Laheru and Dung T Le and Ki Young Chung and Luis A Diaz},
  booktitle={Cancer Chemotherapy and Pharmacology},
  year={2011}
}
Studies treating adenocarcinoma of the pancreas with gemcitabine alone or in combination with a doublet have demonstrated modest improvements in survival. Recent reports have suggested that using the triple-drug regimen FOLFIRINOX can substantially extend survival in patients with metastatic disease. We were interested in determining the clinical benefit of another three-drug regimen of gemcitabine, docetaxel and capecitabine (GTX) in patients with advanced pancreatic adenocarcinoma. The cases… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

Profile and potential of ixabepilone in the treatment of pancreatic cancer

Drug design, development and therapy • 2014
View 3 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 25 references

DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2009
View 1 Excerpt

Phase II trial of GTX chemotherapy in metastatic pancreatic cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2009
View 2 Excerpts

Similar Papers

Loading similar papers…